Øystein Rekdal

Chief Executive Officer at LYTIX BIOPHARMA

Net worth: 79 132 $ as of 30/03/2024

Health Technology

Consumer Services

Profile

Øystein Rekdal is the founder of Lytix Biopharma AS, a company founded in 2003.
He holds the title of Chief Executive Officer at Lytix Biopharma AS starting in 2019.
Dr. Rekdal's current job is as a Professor at the University of Tromso.
He previously worked as a Director at Prophylix AS.
Dr. Rekdal obtained a doctorate degree from the University of Tromso.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
LYTIX BIOPHARMA AS 0.35%	25/08/2022	139,963 ( 0.35% )	79 132 $	30/03/2024

Øystein Rekdal active positions

Companies	Position	Start
LYTIX BIOPHARMA	Chief Executive Officer	10/09/2019
University of Tromso	Corporate Officer/Principal	-

All active positions of Øystein Rekdal

Former positions of Øystein Rekdal

Companies	Position	End
Prophylix AS Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway.	Director/Board Member	-

See the detail of Øystein Rekdal's experience

Training of Øystein Rekdal

University of Tromso

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Øystein Rekdal's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
LYTIX BIOPHARMA	Health Technology

Private companies	1
Prophylix AS Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway.	Health Technology